Ignyta Announces Initiation of STARTRK-1 Global Phase I/II Clinical Trial of …

Ignyta Announces Initiation of STARTRK-1 Global Phase I/II Clinical Trial of …

RXDX-101 has demonstrated in vivo antitumor activity against various TrkA, ROS1 or ALK-driven mouse xenograft models of different human cancers, and has demonstrated oral bioavailability and been observed to efficiently cross the blood brain barrier in …

(Visited 1 times, 1 visits today)
6
Like
Save

Comments

Comments are disabled for this post.